Abstract
Cardiovascular disease is one of the main leading causes of mortality. Approximately, 80% of cardiovascular deaths occur in low- and middle-income countries (LMICs). Current guidelines which are based on randomized controlled trials direct the cardiovascular diagnosis and treatment. Yet, such guidelines do not benefit every patient. Recent studies question the ‘one size fits all’ principle particularly in complex traits such as thrombosis. The cost and duration of genetic testing continue to decline rapidly and novel strategies are on the rise to determine individual susceptibility to diseases and responses to therapy. Multidimensional evaluation of the patient with his/her environment, genomics, detailed medical history, and compliance to treatment are crucial in preventing complications from antithrombotic treatment. In this review, we discuss some of the pharmacogenomic features of antithrombotic medications that are currently used. We believe current personalized medicine and pharmacogenomics are pivotal in elucidating contradictory results of randomized controlled trials to test the same antithrombotic regimen on all participants.
Keywords: Antiplatelet, antithrombotic theraphy, aspirin, cardiovascular therapeutics, clopidogrel, personalized medicine, pharmacogenomics.
Current Pharmacogenomics and Personalized Medicine
Title:Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries
Volume: 12 Issue: 3
Author(s): Pinar Kuru and Mehmet Agirbasli
Affiliation:
Keywords: Antiplatelet, antithrombotic theraphy, aspirin, cardiovascular therapeutics, clopidogrel, personalized medicine, pharmacogenomics.
Abstract: Cardiovascular disease is one of the main leading causes of mortality. Approximately, 80% of cardiovascular deaths occur in low- and middle-income countries (LMICs). Current guidelines which are based on randomized controlled trials direct the cardiovascular diagnosis and treatment. Yet, such guidelines do not benefit every patient. Recent studies question the ‘one size fits all’ principle particularly in complex traits such as thrombosis. The cost and duration of genetic testing continue to decline rapidly and novel strategies are on the rise to determine individual susceptibility to diseases and responses to therapy. Multidimensional evaluation of the patient with his/her environment, genomics, detailed medical history, and compliance to treatment are crucial in preventing complications from antithrombotic treatment. In this review, we discuss some of the pharmacogenomic features of antithrombotic medications that are currently used. We believe current personalized medicine and pharmacogenomics are pivotal in elucidating contradictory results of randomized controlled trials to test the same antithrombotic regimen on all participants.
Export Options
About this article
Cite this article as:
Kuru Pinar and Agirbasli Mehmet, Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries, Current Pharmacogenomics and Personalized Medicine 2014; 12 (3) . https://dx.doi.org/10.2174/1875692112666141027231225
DOI https://dx.doi.org/10.2174/1875692112666141027231225 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Essential Roles of Toll-Like Receptors in Atherosclerosis
Current Medicinal Chemistry Hypothyroidism and Endothelial Function: A Marker of Early Atherosclerosis?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Ischemic and Oxidative Damage to the Hypothalamus May Be Responsible for Heat Stroke
Current Neuropharmacology A Review on Experimental Methods for Diabetes Induction and Therapeutic Efficacy of Anti-diabetic Drug Loaded Nanoformulation
Current Drug Therapy Beneficial Effects of Herbs, Spices and Medicinal Plants on the Metabolic Syndrome, Brain and Cognitive Function
Central Nervous System Agents in Medicinal Chemistry The Emergence of Plasma Membrane Calcium Pump as a Novel Therapeutic Target for Heart Disease
Mini-Reviews in Medicinal Chemistry Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
Current Vascular Pharmacology The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology Risk Factors for Development of Heart Failure
Current Cardiology Reviews Is Programmed Aging a Cause for Optimism?
Current Aging Science Ginger and Heart Health: From Mechanisms to Therapeutics
Current Molecular Pharmacology Editorial (Thematic Issue: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps)
Current Cardiology Reviews Actions of Selected Cardiovascular Hormones on Arterial Stiffness and Wave Reflections
Current Pharmaceutical Design Current Outcomes and Considerations in Hypoplastic Left Heart Syndrome
Current Pediatric Reviews Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets The Role of Physical Exercise and Omega-3 Fatty Acids in Depressive Illness in the Elderly
Current Neuropharmacology Complementary Role of Herbal Medicine and Exercise in Cardiovascular Disease Prevention and Management: A Review of Evidence
Current Pharmaceutical Design NOAC in Acute Coronary Syndrome and AF?
Cardiovascular & Hematological Disorders-Drug Targets Nutraceuticals: Beyond the Diet Before the Drugs
Current Bioactive Compounds